ANMCO position paper ‘Hypertrophic cardiomyopathy: from diagnosis to treatment’

Hypertrophic cardiomyopathy (HCM) is a non-rare genetic cardiomyopathy, with an estimated prevalence of 1:500, characterized by an increase in the left ventricular wall thickness in the absence of increased loading conditions. The hypertrophy is mostly asymmetric and predominantly affects the basal septum and anterior wall. Left ventricular outflow tract obstruction, at rest or after provocative tests, is detected in many patients and represents the primary cause of reduced functional capacity, as well as an independent predictor of sudden cardiac death and advanced heart failure. Until ∼1 year ago, symptomatic patients despite maximal therapy with β-blockers or calcium channel blockers plus disopyramide had only basal septal reduction therapy through myectomy or septal alcoholization as additional therapeutic options. Today, a new class of drugs that inhibit cardiac myosin activity is available for patients with obstructive HCM. In light of the new treatment perspectives, the correct clinical-therapeutic classification of affected patients becomes of fundamental importance for the cardiologist. The aim of this position paper is to increase the knowledge of cardiologists in the field of HCM, defining its epidemiological, genetic, and pathological characteristics, identifying the diagnostic criteria and instrumental methods capable of stratifying the risk profile, with the aim of an optimal therapy tailored on the single patient.

Authors

Institutions

Publication Details

Journal
European Heart Journal Supplements
Published
2025-03-07
DOI
https://doi.org/10.1093/eurheartjsupp/suaf077
Citations
1
Primary Topic
Cardiomyopathy and Myosin Studies
Type
article
Field-Weighted Citation Impact
1.39
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ANMCO position paper ‘Hypertrophic cardiomyopathy: from diagnosis to treatment’

Alessandro Navazio, Massimo Grimaldi, Federica Re, Andrea Montalto et al.
1 citations
European Heart Journal Supplements
Cardiomyopathy and Myosin Studies
1.39
article

ANMCO position paper ‘Hypertrophic cardiomyopathy: from diagnosis to treatment’

Alessandro Navazio, Massimo Grimaldi, Federica Re, Andrea Montalto, Attilio Iacovoni, Piero Gentile, Maria Rosaria Iascone, Enrica Perugini, Francesca Girolami, Michele Emdin, Giancarlo Todiere, Laura Scelsi, Iacopo Olivotto, Vittorio Pascale, Benedetta De Chiara, Cristina Chimenti, Daniele Pasqualucci, C Ciampi, Andrea Matteucci, Claudio Bilato, Carla Lofiego, Maurizio Pieroni, Michele Massimo Gulizia, Santo Dellegrottaglie, Emanuele Tizzani, Furio Colivicchi, Domenico Gabrielli, Federico Nardi, Pietro Scicchitano, Leonardo De Luca, Irene Bottillo, Giovanna Geraci, Samuele Pentiricci, Paola Grammatico, Giovanni Quarta, Cristina Basso, Carmine Riccio, Maria Alfarano, Monica De Gaspari, Eluisa La Franca, Marco Corda, Fabrizio Oliva, Massimo Milli, Massimo Di Marco
article en
1 citations

Abstract

Hypertrophic cardiomyopathy (HCM) is a non-rare genetic cardiomyopathy, with an estimated prevalence of 1:500, characterized by an increase in the left ventricular wall thickness in the absence of increased loading conditions. The hypertrophy is mostly asymmetric and predominantly affects the basal septum and anterior wall. Left ventricular outflow tract obstruction, at rest or after provocative tests, is detected in many patients and represents the primary cause of reduced functional capacity, as well as an independent predictor of sudden cardiac death and advanced heart failure. Until ∼1 year ago, symptomatic patients despite maximal therapy with β-blockers or calcium channel blockers plus disopyramide had only basal septal reduction therapy through myectomy or septal alcoholization as additional therapeutic options. Today, a new class of drugs that inhibit cardiac myosin activity is available for patients with obstructive HCM. In light of the new treatment perspectives, the correct clinical-therapeutic classification of affected patients becomes of fundamental importance for the cardiologist. The aim of this position paper is to increase the knowledge of cardiologists in the field of HCM, defining its epidemiological, genetic, and pathological characteristics, identifying the diagnostic criteria and instrumental methods capable of stratifying the risk profile, with the aim of an optimal therapy tailored on the single patient.

European Heart Journal SupplementsVol. 27(Supplement_5)
Policlinico Umberto I (IT), Ospedale Maggiore (IT), Azienda Ospedaliera San Camillo-Forlanini (IT), Associazione Nazionale Medici Cardiologi Ospedalieri (IT), Ospedale Garibaldi (IT), Ospedale Papa Giovanni XXIII (IT), Ospedale di Santo Spirito (IT), Meyer Children's Hospital (IT), Presidio Ospedaliero (IT), Ospedale Generale Regionale Francesco Miulli (IT), Azienda Ospedale - Università Padova (IT), Ospedale Sant'Anna (IT), Policlinico San Matteo Fondazione (IT), Ospedale degli Infermi (IT), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Azienda Usl Toscana Centro (IT), Fondazione Toscana Gabriele Monasterio (IT), Azienda Ospedaliera G. Brotzu (IT), Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione (IT), University of Milano-Bicocca (IT), Sapienza University of Rome (IT)
Openalex Percentile: Top 19%
Cardiomyopathy and Myosin Studies
1.39
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.